On September 28th 2014 Clovis Oncology CLVS announced that it had reported positive results in a phase 2 clinical trial in treating patients with Ovarian Cancer. The phase 2 trial was known as the ARIEL2 study and had recruited 20 patients to take 600 mg of a drug compound known as Rucaparib. Rucaparib is an oral inhibitor pill that these patients take to inhibit the genes of the Ovarian cancer known as PARP-1 and PARP-2. This type of Ovarian Cancer is a type where patients have a BRCA mutation gene. This means that this cancer is a type of a rare cancer that occurs in ovarian cancer patients. Clovis though is currently using Rucaparib to target tumors with defective DNA repair functions. The first two initial tumors being targeted are in Ovarian Cancer and Pancreatic Cancer.

The company stated that of those patients taking Rucaparib, 95% (14 out of 15) had a Disease Control Rate -- DCR. DCR means that the patients in the study either had a complete response, partial response, or a stable disease. This bodes well for the compound as it shows that patients being treated are able to not only control the spread of the cancer but somewhat prohibit it from forming. Eight of the twelve patients that achieved a partial response in the trial did so in week 6 of taking the drug compound. These preliminary data were presented at a conference in Madrid known as ESMO -- European Society Of Medical Oncology. As we can see in this early clinical evidence Clovis Oncology seems to be doing well with its Rucaparib drug compound, and still has additional oncology compounds in its pipeline.

There are about 21,980 cases of Ovarian Cancer in the United States in 2014 thus far  and a limited amount of treatment options for these patients. Clovis even discovered in its trial that patients without the BRCA gene Ovarian Cancer still benefited with treatment from using Rucaparib. This finding can be established in new phase 2 trials later down the line in other Ovarian Cancer patients. The stock surged on Monday September 29, 2014  by 13% on the news, but today has declined down by 6% to close the day at $45.36 per share. Clovis Oncology is an attractive oncology company with variety of clinical compounds that may help improve the lives of these cancer patients.

We believe that Clovis Oncology should not be ignored because as it stands now the company is set up to be possibly bought out by another big pharmaceutical company that may want to add to their oncology pipeline. We believe that Clovis would be a great investment for investors looking for future growth and potential acquisition target. Investors should definitely keep an eye on this biotech stock in the coming months. Matter in fact Clovis expects to report additional phase 2 trial data on this ARIEL2 study in patients with Ovarian Cancer this coming November at a Symposium conference. This should give another catalyst for the share of Clovis and should provide investors with further guidance on the future of the company's direction with its cancer compounds.